Setup, so nobody has to ask: oral semaglutide · forty-two days.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Concretely, what should I do, and how would I know afterwards whether I did it right?
42 days past a due dose is 6 half-lives at the seven-day half-life this class runs on, which leaves about 1.6 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(42÷7) = 0.0156. At 1.6 per cent this is a washout rather than a late dose. 42 days is the scenario the escalation schedule was written for. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
Published missed-dose guidance for the weekly agents in this class specifies a window of about five days, derived directly from the half-life.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
edited 1 Nov 2025 by sample_id — removed a claim I could not source
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
A published missed-dose window applies to a licensed product with a known content, which unverified material is not.
Set a recurring reminder attached to something you already do weekly.
Changing the regular dosing day is possible and should be done by moving forward, not by squeezing two doses together.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
To change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
To move your dosing day, move it later and keep three days between doses.
This is one of the questions where the pharmacokinetics gives a reassuring answer and the anxiety persists anyway.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.
Never double up. Peak exposure is what drives the symptoms.
The relevant arithmetic is that one missed dose of a weekly agent produces a trough about half the usual, which is well inside the normal range.
One missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.
Peak exposure rather than average exposure drives gastrointestinal tolerability, which is the reason doubling up is advised against.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Two or more missed weekly doses means considering a lower restarting step.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.